Ran Frenkel - 17 Feb 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Dev. Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Ran Frenkel
Issuer symbol
KPTI
Transactions as of
17 Feb 2022
Net transactions value
-$35,509
Form type
4
Filing time
22 Feb 2022, 15:16:24 UTC
Previous filing
09 Feb 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $35,509 -2,929 -2.8% $12.12* 101,703 17 Feb 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 17, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.